Transcell Biologics, a Hyderabad-based leader in stem cell technology, has recently secured an undisclosed investment from Boston-based Quantiphi and the Indian Angel Network (IAN). The funding will propel the company’s efforts to broaden its client base and enhance the implementation of its innovative Digital Animal Replacement Technology (DART) across the global bio and pharmaceutical sectors.
Founded in 2009 by Subadra Dravida, Transcell Biologics focuses on maximizing stem cell yield while preserving pluripotency and functionality. The company is renowned for its proprietary processes and has significantly diversified its applications in stem cell technologies.
DART, Transcell Biologics’ flagship solution, offers a cutting-edge approach to animal-free testing. By integrating human MicroPhysiological Systems (hMPS) technology with AI/ML-driven in silico platform configurations, DART streamlines and automates bioassay processes. This results in statistically compliant reports and addresses safety and efficacy concerns for drugs and vaccines intended for human use.
The DART technology has already garnered substantial attention in the Indian market, with numerous biopharmaceutical companies incorporating it into their high-impact programs. Transcell Biologics now aims to extend its reach to the USA, Europe, and Japan, leveraging the new investment to accelerate growth and global adoption of its enterprise solution.
The backing from Quantiphi and IAN underscores the growing confidence in Transcell Biologics’ potential to revolutionize the bio and pharmaceutical testing landscape.
